These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12089373)

  • 1. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.
    Cao Z; Bonnet F; Candido R; Nesteroff SP; Burns WC; Kawachi H; Shimizu F; Carey RM; De Gasparo M; Cooper ME
    J Am Soc Nephrol; 2002 Jul; 13(7):1773-87. PubMed ID: 12089373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis.
    Cao Z; Kelly DJ; Cox A; Casley D; Forbes JM; Martinello P; Dean R; Gilbert RE; Cooper ME
    Kidney Int; 2000 Dec; 58(6):2437-51. PubMed ID: 11115077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism.
    Cao Z; Cox A; Bonnet F
    Exp Nephrol; 2002; 10(1):19-25. PubMed ID: 11803201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis.
    Madrid MI; García-Salom M; Tornel J; De Gasparo M; Fenoy FJ
    Am J Physiol; 1997 Nov; 273(5):R1676-82. PubMed ID: 9374809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.
    Yu XQ; Wu LL; Huang XR; Yang N; Gilbert RE; Cooper ME; Johnson RJ; Lai KN; Lan HY
    Kidney Int; 2000 Oct; 58(4):1469-80. PubMed ID: 11012882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
    Siragy HM; El-Kersh MA; De Gasparo M; Webb RL; Carey RM
    J Hypertens; 2002 Jun; 20(6):1157-63. PubMed ID: 12023686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation.
    Hilgers KF; Hartner A; Porst M; Veelken R; Mann JF
    Circulation; 2001 Sep; 104(12):1436-40. PubMed ID: 11560862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
    Abdel-Rahman EM; Abadir PM; Siragy HM
    Am J Physiol Regul Integr Comp Physiol; 2008 Nov; 295(5):R1473-8. PubMed ID: 18799632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
    Abadir PM; Carey RM; Siragy HM
    Hypertension; 2003 Oct; 42(4):600-4. PubMed ID: 12953015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury.
    Hilgers KF; Hartner A; Porst M; Mai M; Wittmann M; Hugo C; Ganten D; Geiger H; Veelken R; Mann JF
    Kidney Int; 2000 Dec; 58(6):2408-19. PubMed ID: 11115074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system.
    Wu LL; Cox A; Roe CJ; Dziadek M; Cooper ME; Gilbert RE
    J Am Soc Nephrol; 1997 Sep; 8(9):1373-82. PubMed ID: 9294828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury.
    Cao Z; Cooper ME; Wu LL; Cox AJ; Jandeleit-Dahm K; Kelly DJ; Gilbert RE
    Hypertension; 2000 Oct; 36(4):561-8. PubMed ID: 11040236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
    Siragy HM; de Gasparo M; El-Kersh M; Carey RM
    Hypertension; 2001 Aug; 38(2):183-6. PubMed ID: 11509473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.
    Hulthén UL; Cao Z; Rumble JR; Cooper ME; Johnston CI
    Am J Hypertens; 1996 Sep; 9(9):895-901. PubMed ID: 8879346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
    Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
    Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.
    Sandmann S; Yu M; Unger T
    Br J Pharmacol; 2001 Feb; 132(3):767-77. PubMed ID: 11159730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The therapeutic effects of bosentan and valsartan on renal interstitial fibrosis of chronic aristolochic acid nephropathy].
    Zhang C; Chen YP; Dong HR; Qiu CB
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(37):2601-6. PubMed ID: 16321319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.